Experienced leader in development, validation, and implementation of clinical trial software and processes

Lech Garus is attending the DS&AI F2F in Madrid 05.2023. Lech works in the system support as the Senior Systems Manager. Lech comes from Poland and lives in Warsaw. Lech loves paragliding and bread baking.

We met at DS&AI Madrid meeting. I was the the English bloke who works in clinical trials.

I am Subhead of Systems Support in DS3 and look forward to network with you further.

Professional with extensive experience in analyzing, designing, and implementing novel solutions through the use of Machine Learning for its applications in Research and Development for the Healthcare and Pharmaceutical Industry. I employ my interpersonal communication, business, and technology integration talents to set product strategy and create product roadmaps in an agile environment. • Talent Management • Team-Player • Effective Communicator • Detail Oriented • Analytical Mindset • Computer Vision • Machine Learning • Natural Language Processing • Data Analysis • Statistical Modeling

Given the considerable amount of data that is collected throughout clinical trials, it can be asked if this data can be used to improve our understanding of the trial, regardless of outcome. The radiomics pilot seeks to provide a toolkit that is capable of analyzing the different modalities of information found in clinical trials (genome, gene expression, biomarker, clinical information, and imaging information) to derive insights into why a patient may be responding, or why a clinical trial was unsuccessful. The current efforts have focused on clinical trials in oncology, while collaborating with the RED-ONC function. Overall, the project is in its pilot state, and demonstrating a proof of concept, while documenting many challenges and learnings with the development of such a toolkit. Potential directions that could expand this toolbox include deriving the factors that best predict why a patient would stay in a clinical trial, and providing assistance with patient selection of clinical trials. Other potential directions involve suggesting why a particular trial may have been unsuccessful and providing that information back to the drug development team.